TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* -Pathologically confirmed NPC~* Completed a definitive course of intensity-modulated photon radiation therapy (IMXT) to a total dose of ≥ 66 Gy~* Recurrence diagnosed more than 12 months after the initial course of IMXT~* Age ≥ 18 and \< 70 years of age~* Karnofsky Performance Score ≥70~* Willing to accept adequate contraception for women with childbearing potential~* Ability to understand character and individual consequences of the clinical trial~* Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial~Exclusion Criteria:~* Local recurrence of NPC diagnosed within 12 months from the completion of previous course of radiation therapy~* Presence of distant metastasis~* Technology used other than IMXT (including brachytherapy following IMXT) for the treatment of initial diagnosis of NPC~* Pregnant or lactating women~* Patients who have not yet recovered from acute toxicities of prior therapies~* A diagnosis of malignancy other than CIS of the cervix, BCC and SCC of the skin within the past 5 years~* Refusal of the patient to participate into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CIRT with concurrent chemo arm (Type: EXPERIMENTAL): Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m\^2, weekly).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subfoveal Choroidal Thickness in Thai Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or above~* Healthy subjects~* No ocular diseases~* Written informed consent form~Exclusion Criteria:~* patients with systemic diseases that may affect retinal or choroidal thickness including diabetes~* patients with history of refractive surgeries, intraocular surgeries or retinal laser treatments~* patients with history of macular, retinal, or optic nerve abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: None): to measure the subfoveal choroidal thickness in healthy volunteers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional Neuroimaging and Genetic Vulnerability to Suicidal Behavior

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* right-handed~* arm suicidal : Personal history of unipolar depressive disorder or bipolar disorder and having realized in his life at least one suicide attempt~* arm emotional Witnesses : Personal history of unipolar depressive disorder or bipolar disorder and have never done in his life attempted suicide~* arm healthy Witnesses : any current or past personal history of psychiatric disorders of Axis I and have never done in his life attempted suicide~Exclusion Criteria:~* Cons-indications to the use of MRI~* Existence of a past history of head trauma with loss of consciousness or neurological brain disorder or secondary neurological suffering suicidal gesture.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- healthy volunteers (Type: OTHER): subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
- emotional witness (Type: OTHER): subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
- patient suicide (Type: OTHER): subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have recalcitrant, quiescent, alopecia areata, non-responsive to treatment, for at least 6 months.~2. Subject must have one patch of alopecia areata greater than 5 cm diameter, of two patches of alopecia areata, each greater than 2.5 cm diameter.~Exclusion Criteria:~1. Subjects with active, progressive, alopecia areata.~2. Subjects who are actively experiencing significant spontaneous regrowth of terminal hair.~3. Subjects with autoimmune deficiency.~4. Subjects with a medical condition contraindicating use of anesthesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- alopecia areata (Type: EXPERIMENTAL): pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Fever Prevention in Brain Injured Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted with a primary neurological diagnosis of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage~2. Prior to onset of acute symptoms, was considered functionally independent (mRS 0-2)~3. Meets disease-specific criteria~Exclusion Criteria:~1. Fever (≥38°C) prior to study enrollment~2. Pre-existing neurological, psychiatric, or other condition that would confound neurological assessment or would make it difficult to accurately assess neurologic and/or functional outcome~3. Has a pre-morbid condition with poor likelihood of survival to 6 months~4. Has a pre-morbid mRS ≥3~5. Diagnosed with brain death~6. Is undergoing therapeutic hypothermia therapy~7. Has sustained neurological injury felt to be catastrophic with little chance of recovery~8. Has a skin condition in which the use of the ArcticGel Pads is contraindicated (i.e., skin that has signs of ulceration, burns, hives, or rash)~9. Has poor skin integrity or poor tissue perfusion~10. Participation in a concurrent investigational / interventional study (medical device or drug)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Fever Prevention (Type: EXPERIMENTAL): Fever will be prevented using a surface targeted temperature management system
- Standard Care (Type: ACTIVE_COMPARATOR): Standard care in which fever may spontaneously develop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Gastroesophageal pathology erosive or non-erosive and acute or chronic treated with Rabeprazol per clinical practice~Exclusion Criteria:~* Patients pregnant or lactating~* Other gastrointestinal pathologies~* Intestinal or gastric survey~* Other severe concomitant pathologies~* Drug abuse or use of NSAIs (Non-Steroidal Anti-Inflammatories) more than 3 days/week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: None): None
- 002 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-documented high-risk endometrioid adenocarcinoma with no visible residual disease, defined by the following criteria:~  * Surgical stage I disease with \< 50 myometrial invasion and grade 3 tumor (IAG3) with lymphovascular space involvement;~ * Surgical stage I disease with \>= 50% myometrial invasion and grade 2 or 3 tumor (IBG2, IBG3);~ * Any surgical stage II disease (II);~ * Any surgical stage III disease (IIIA, IIIB, IIIC); and~ * Any surgical stage IV disease with no residual macroscopic tumor~* Surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings as per standard Gynecologic Oncology Group (GOG) criteria~* Eastern Cooperative Oncology Group (ECOG) performance status of \< 2~* Written voluntary informed consent~Exclusion Criteria:~* Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) \> 2.5 times the institutional upper limit of normal~* Total serum bilirubin \> 1.5 mg/dl~* History of chronic or active hepatitis~* Serum creatinine \> 2.0 mg/dl~* Platelets \< 100,000/mm\^3~* Absolute neutrophil count (ANC) \< 1500/mm\^3~* Hemoglobin \< 8.0 g/dl (the patient may be transfused prior to study entry)~* Patient has severe or uncontrolled concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)~* Patient with any prior chemotherapy or radiotherapy for pelvic malignancy~* Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry~* Patients with any history of cancer with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the past five years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (paclitaxel, carboplatin, radiation therapy) (Type: EXPERIMENTAL): CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of the Incidence of PICS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are \< or = to 18 years of age and have an anticipated length of PICU stay of \> or = to 14 days from June 1, 2018 through January 31, 2019~Exclusion Criteria:~* Chronic mechanical ventilation, Known chronic inflammatory disease process, or Diagnosed with failure to thrive or malnutrition upon admission to the PICU

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The OneFlorida Cancer Control Alliance: Implementing the 6As in Pediatric Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 11-17 years old~Exclusion Criteria:~* 18 years and older

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Control Clinic (Type: NO_INTERVENTION): The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
- Intervention Clinic (Type: EXPERIMENTAL): Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: VISIODOL: Validation of the VISIODOL® Scale

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Subjects aged over 18 / under 60~* Male or female~* Subjects fasting from coffee, tea, Coca-Cola and others stimulants~* Sufficient understanding and cooperation to comply with the study requirements~* Agreed to provide written consent~* Affiliated to the social security~* Subjects with visual impairment (congenital or acquired)~* Subjects with no visual impairment (healthy group)~Exclusion Criteria:~* Subjects under 18 years old~* Administrative and legal criteria (tutorship, curatorship, without social security, in exclusion period of another study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Healthy volunteer group (Type: ACTIVE_COMPARATOR): male or female healthy volunteers
- Subjects with acquired visual impairment (Type: EXPERIMENTAL): visual acquired disability
- Subjects with congenital visual impairment (Type: EXPERIMENTAL): Visual congenital disability

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide in Myocardial Infarction Size

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction and electrocardiographic evidence of ST elevation~* No clinical evidence of congestive heart failure~* All patients must undergo successful percutaneous coronary intervention for thrombolysis in myocardial infarction (TIMI) 0 or 1 coronary flow with resulting TIMI 2 or 3 flow~* Greater than 18 years of age~* Signed Institutional Review Board (IRB) approved informed consent~Exclusion Criteria:~* Prior myocardial infarction~* Requirement for urgent cardiac surgery~* Previous coronary artery bypass graft (CABG) or primary coronary intervention (PCI)~* Left bundle branch block~* Heart block that is expected to require a temporary pacemaker for greater than 72 hours~* Prior use of thrombolytic therapy for the current event~* Unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium contrast media, including patients with a calculated creatinine clearance less than 60 ml/min/1.73m² Body Surface Area (BSA)~* Active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6 weeks prior~* Neutropenia (WBC \<2000 (mm)³), Anemia (HCT \<30%, Thrombocytopenia (Thrombocytes \<50,000 (mm)³). It is not necessary to confirm blood counts prior to start of study drug in the absence of clinical suspicion.~* Known or suspected aortic dissection.~* Prior history of pulmonary disease requiring chronic oxygen therapy.~* Pregnancy, lactating, and women of childbearing potential.~* Medical problem likely to preclude completion of the study.~* Use of investigational drugs or device within the 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (Type: EXPERIMENTAL): Inhaled Nitric oxide administered at 80 parts per million (ppm)
- Placebo (Type: PLACEBO_COMPARATOR): Inhaled nitrogen gas (Placebo) administered at 80 ppm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Assessing EmSam in Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18 - 65~2. DSM-IV Bipolar Disorder (I, II, NOS), Depressed Phase~3. DSM-IV Bipolar Disorder (I,II, NOS), Mixed state with adequate mood stabilization (ie, resolution of manic or hypomanic symptoms for 8 weeks with a minimum of 4 weeks on a stable dose of mood-stabilizing medication that will be continued through all phases of the study).~4. Prior failure of or inability to tolerate at least one other antidepressant treatment~5. Physically healthy~6. Agrees to participate in the study~7. HAM-D 24 \> 10~Exclusion Criteria:~1. Bipolar Disorder (I, II, NOS), Mixed State without adequate mood stabilization~2. Prior significant adverse reaction to EmSam~3. Unstable medical disorder~4. History of epilepsy (febrile seizure o.k.)~5. Current use of any medication that might interact with EnSam.~6. Use within 2 weeks of other antidepressant medication (6 weeks for fluoxetine)~7. Inability to adhere to a tyramine-free diet~8. Recent (past 6 months) suicide attempt~9. Serious suicidal ideation~10. Pregnant~11. Breast feeding~12. Fecund, sexually active females, without adequate contraception~13. Prior failure to respond to 2 or more adequate oral MAOI trials (2/3 PDR maximum dose, minimum 4 weeks)~14. Non-nicotine substance abuse/dependence within the past 6 months (1 year for amphetamines/cocaine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EmSam (Type: EXPERIMENTAL): EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measuring the Effect of Radiation Therapy on Patient Activity Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Breast, Prostate, Lung or Head and Neck Cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Ability to walk 100 feet without rest~* Signed informed consent~Exclusion Criteria:~* Any other noncutaneous cancer diagnosis under active treatment~* Known metastatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Head and Neck (Type: None): Subjects with head and neck cancer receiving radiation therapy.
- Prostate (Type: None): Subjects with prostate cancer receiving radiation therapy.
- Breast (Type: None): Subjects with breast cancer receiving radiation therapy.
- Lung (Type: None): Subjects with lung cancer receiving radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I + II~* Elective intervention under general anesthesia~Exclusion Criteria:~* Reactive airway disease~* Respiratory tract infection (previous 2 weeks)~* Malignant hyperthermia~* Neuromuscular disease~* Cardiac disease

- Gender: ALL
- Minimum Age: 25 Months
- Maximum Age: 84 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues